Related references
Note: Only part of the references are listed.Phosphoinositide 3-Kinase-C2α Regulates Polycystin-2 Ciliary Entry and Protects against Kidney Cyst Formation
Irene Franco et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Spleen Tyrosine Kinase: A Crucial Player and Potential Therapeutic Target in Renal Disease
Terry King-Wing Ma et al.
NEPHRON (2016)
Development of a 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases
Tijmen H. Booij et al.
JOURNAL OF BIOMOLECULAR SCREENING (2016)
Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
Hannah A. Blair et al.
DRUGS (2015)
A polycystin-centric view of cyst formation and disease: the polycystins revisited
Albert C. M. Ong et al.
KIDNEY INTERNATIONAL (2015)
Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing
Francis Robert et al.
GENOME MEDICINE (2015)
TNFα Signaling Regulates Cystic Epithelial Cell Proliferation through Akt/mTOR and ERK/MAPK/Cdk2 Mediated Id2 Signaling
Julie X. Zhou et al.
PLOS ONE (2015)
Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas
Jennifer L. Anderson et al.
PLOS ONE (2015)
Polycystins and partners: proposed role in mechanosensitivity
Kevin Retailleau et al.
JOURNAL OF PHYSIOLOGY-LONDON (2014)
Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease
Vicente E. Torres et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Dimeric CRISPR RNA-guided Fokl nucleases for highly specific genome editing
Shengdar Q. Tsai et al.
NATURE BIOTECHNOLOGY (2014)
Activation of the PI3K/mTOR Pathway Is Involved in Cystic Proliferation of Cholangiocytes of the PCK Rat
Xiang Shan Ren et al.
PLOS ONE (2014)
Ultra High Content Image Analysis and Phenotype Profiling of 3D Cultured Micro-Tissues
Zi Di et al.
PLOS ONE (2014)
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
Kerstin Maria Kampa-Schittenhelm et al.
MOLECULAR CANCER (2013)
The ciliary flow sensor and polycystic kidney disease
Fruzsina Kotsis et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2013)
Dose-Dependent Effects of Sirolimus on mTOR Signaling and Polycystic Kidney Disease
Zlata Novalic et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Polycystin-1, 2, and STIM1 Interact with IP3R to Modulate ER Ca2+ Release through the PI3K/Akt Pathway
Netty G. Santoso et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2011)
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
Luis I. Toledo et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
Matthew T. Burger et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer
Qingsong Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-I receptor and insulin receptor
Mark J. Mulvihill et al.
FUTURE MEDICINAL CHEMISTRY (2009)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
Carson C. Thoreen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
The third dimension bridges the gap between cell culture and live tissue
Francesco Pampaloni et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system
E. Parker et al.
KIDNEY INTERNATIONAL (2007)
Autosomal dominant polycystic kidney disease
Vicente E. Torres et al.
LANCET (2007)
Inhibition of HER-2(neu/ErbB2) restores normal function and structure to polycystic kidney disease (PKD) epithelia
Samantha J. Wilson et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2006)
The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease
JM Shillingford et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Modelling glandular epithelial cancers in three-dimensional cultures
J Debnath et al.
NATURE REVIEWS CANCER (2005)
Lentiviral vectors efficiently transduce quiescent mature 3T3-L1 adipocytes
F Carlotti et al.
MOLECULAR THERAPY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han : SPRD rats
VE Torres et al.
KIDNEY INTERNATIONAL (2003)
Share Paper
